Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
François Raffi(Nantes Université), Hans Jaeger(MUC Research (Germany)), Eugenia Quirós-Roldán(University of Brescia), Helmut Albrecht(Palmetto Health Richland), Elena Belonosova(Orel Regional Academy of Public Administration), José M. Gatell(Hospital Clínic de Barcelona), Jean-Guy Baril, Peré Domingo(Hospital San Juan de la Cruz), Clare Brennan(Research Triangle Park Foundation), Steve Almond(GlaxoSmithKline (Canada)), Sherene Min(GlaxoSmithKline (United States))
Cited by 372
Abstract
Related Papers
No related papers found
Powered by citation graph analysis